BRPI0512593A - composto ou um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, e, métodos de inibir a quinase 1 de ponto de verificação em uma célula, de sensibilizar células em um indivìduo e de inibir a proliferação de célula aberrante - Google Patents

composto ou um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, e, métodos de inibir a quinase 1 de ponto de verificação em uma célula, de sensibilizar células em um indivìduo e de inibir a proliferação de célula aberrante

Info

Publication number
BRPI0512593A
BRPI0512593A BRPI0512593-6A BRPI0512593A BRPI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A
Authority
BR
Brazil
Prior art keywords
inhibiting
methods
solvate
compound
pharmaceutically acceptable
Prior art date
Application number
BRPI0512593-6A
Other languages
English (en)
Inventor
Laurence Edward Burgess
Adam Wade Cook
Kimba L Fischer
Stephen T Schlachter
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BRPI0512593A publication Critical patent/BRPI0512593A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO OU UM SAL OU PRó-DROGA OU SOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO, E, MéTODOS DE INIBIR A QUINASE 1 DE PONTO DE VERIFICAçãO EM UMA CéLULA, DE SENSIBILIZAR CéLULAS EM UM INDIVìDUO E DE INIBIR A PROLIFERAçãO DE CéLULA ABERRANTE Compostos de uréia substituídos por afila e heteroarila úteis no tratamento de doenças e condições relacionadas ao dano ao DNA ou lesões na replicação do DNA são divulgados. Os métodos de fabricar os compostos, e seu uso como agentes terapêuticos, por exemplo, no tratamento do câncer e outras doenças caracterizadas por deficiências na replicação do DNA, segregação cromossómica, ou divisão celular também são divulgados.Fórmula (I)
BRPI0512593-6A 2004-06-25 2005-06-24 composto ou um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, e, métodos de inibir a quinase 1 de ponto de verificação em uma célula, de sensibilizar células em um indivìduo e de inibir a proliferação de célula aberrante BRPI0512593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58308004P 2004-06-25 2004-06-25
PCT/US2005/022515 WO2006012308A1 (en) 2004-06-25 2005-06-24 Bisarylurea derivatives useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
BRPI0512593A true BRPI0512593A (pt) 2008-03-25

Family

ID=35307890

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512593-6A BRPI0512593A (pt) 2004-06-25 2005-06-24 composto ou um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, e, métodos de inibir a quinase 1 de ponto de verificação em uma célula, de sensibilizar células em um indivìduo e de inibir a proliferação de célula aberrante

Country Status (9)

Country Link
EP (1) EP1765808A1 (pt)
JP (1) JP2008504283A (pt)
KR (1) KR20070028591A (pt)
CN (1) CN101006075A (pt)
AU (1) AU2005267185A1 (pt)
BR (1) BRPI0512593A (pt)
CA (1) CA2571424A1 (pt)
MX (1) MX2007000259A (pt)
WO (1) WO2006012308A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510719A (ja) * 2004-08-19 2008-04-10 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
HRP20100678T1 (hr) 2005-03-29 2011-02-28 Icos Corporation Derivati heteroariluree korisni kao inhibitori chk1
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
WO2023287839A2 (en) * 2021-07-13 2023-01-19 Brown University Urinary tract cancer treatment guided by mutational landscape
CA3233080A1 (en) * 2021-09-28 2023-04-06 Pioneer Hi-Bred International, Inc. Seedling germination and growth conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (ja) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> 有機非線形光学材料
JPH09249628A (ja) * 1996-03-12 1997-09-22 Tanabe Seiyaku Co Ltd フェノール誘導体
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7211575B2 (en) * 2001-09-13 2007-05-01 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors

Also Published As

Publication number Publication date
JP2008504283A (ja) 2008-02-14
AU2005267185A1 (en) 2006-02-02
CN101006075A (zh) 2007-07-25
WO2006012308A1 (en) 2006-02-02
KR20070028591A (ko) 2007-03-12
MX2007000259A (es) 2007-07-20
CA2571424A1 (en) 2006-02-02
EP1765808A1 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
BRPI0108841B8 (pt) derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica
BRPI0511512A (pt) derivados pirrolpirimidina úteis no tratamento do cáncer
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
NI201000002A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k.
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TN2010000167A1 (en) Organic compounds
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
TNSN07369A1 (en) Heteroaryl urea derivatives useful for inhibiting chki
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
JP6804540B2 (ja) スルファミド誘導体およびその製造方法と応用
TW200740805A (en) Novel compounds
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.